1. Larsen & Toubro
L&T is a big beneficiary of the various infrastructure proposals announced in the recent Budget. The company has had a great execution history, exhibited financial strength, and created value over the years. The company has delivered ROEs of 14% consistently over the last 10 years, with operating margins of over 15% over this period. Yet, it continues to trade at attractive valuations with a PE under 15x, making it an attractive value-buy.
2. Dr. Reddy's
Now, with the rise in Covid-19 cases and the need for medical support, demand for drugs has skyrocketed and boosted sales of players like Dr. Reddy's, who has been a consistent performer by delivering stable net profit growth at 14% CAGR over the last 10 years. Pharma stocks have been underperformers for the past few years, and with several tailwinds on their side currency, things seem to be rosy, especially for this stock.
3. Dr. Lal Pathlabs
Dr. Lal Pathlabs, too, has been witnessing a rise in testing diagnostic volumes around COVID-10. But had it not been for Covid, it would have still performed well, given that it's been a consistent cash flow generator and has delivered ROCE's more than 30%.
4. Vinati Organics
In line with rising pharma, the growth in chemical stocks is recently trending. China is at a disadvantage, exports from India have ramped up, and Vanati Organics is a strong contender as a leading producer of IBB. It has delivered ROCEs of over 35% over the last 10 years and has growing profits at 24% CAGR.
5. Pidilite Ltd
Pidilite Ltd has been another promising player in the chemical space. The company has a near-monopoly in both industrial and consumer adhesives as well as associates solutions. It has leveraged its positions well enough to consistently deliver excellent shareholder returns and can be a good buy for your portfolio.
6. Coverage
Further adding to the defensive in your portfolio, a mid-cap IT player such as Coforge can be a good pick because it has been continuously increasing its deal wins and has been ramping up on acquisitions to boost its capabilities in the BPM and digital solutions space, thereby benefiting shareholders. With the tech upcycle in place, quality players such as Coforge stand to continue delivering impressive returns to shareholders over the long term.
7. Kotak Mahindra Bank
Amidst the pandemic, the government took effective steps to ensure that credit availability was not an issue for business people. In fact, the RBI reduced interest rates and announced moratoriums for borrowers to give them relief. While this was a positive step, many banks have been cautious and made sufficient provisions to safeguard their assets. Kotak Mahindra Bank is one such bank that raised funds at the start of the pandemic and has been extremely cautious when it comes to lending. It has been maintaining the quality of its book and has been consistently delivering 20%+ CAGR growth in profits since the past 10 years.
8. HDFC Ltd
Another player benefitting from lower rates is HDFC Ltd. This NBFC has the brand, an experienced leadership team, and the market share in loans, making it a true leader.
9. SBI Life Insurance
Insurance is another theme that has recently picked upstream and has huge growth opportunities given its underpenetrated nature. After LIC, SBI Life Insurance is among the best private insurance player with a leading APE growth (20%+). The company commands a strong market share and continues to gain as it offers many products, with FDI limits in insurance now extended. Players like SBI Life are bound to be at an advantage.
10. CSDL
CSDL is a depository that will continue to upscale and benefit. Being in a duopoly with NSDL, CSDL has created a strong market for itself and will continue to gain revenue as markets mature and volumes rise.
I READ YOUR WHOLE ARTICLE, PLEASE READ MY ARTICLE. WE SHOULD SUPPORT EACH OTHER TO MOVE FORWARD THANKS, SIR. NAME IS MY ARTICLE TOP 5 "HORROR PLACES OF INDIA IN PRESENT TIME". I ALWAYS SUPPORT YOU.
You must be logged in to post a comment.